Gall MA et al.
Note that scales on y axis differ. Lanecet ; IV. Hámori Napok, Pécs 24 A RAS-gátlás vérnyomás csökkentéstől független terápiás hatásai Következtetések Antihypertensiv hatástól függetlenűl cardiovasculo-nephroprotectív hatású Bizonyos betegségekben, vagy hypertonia nélkül is előforduló kórállapotokban kedvező terápiás hatása van tumor, pitvarfibrillatio, stb.
Willenheimer R, et al.
- A RAAS-gátlás vérnyomáscsökkentéstől független terápiás hatásai - ppt letölteni
- A vernyomascelertekek eleresevel csokkentheto a cardiovascularis szovodmenyek kockazata.
Eur Heart J. J Vasc Res. J Clin Invest. J Hypertens.
Arch Intern Med. N Engl J Med. The combination was well tolerated, even in those patients with advanced renal insufficiency. When there is NO reduction in proteinuria, there is also no change in the time to dialysis.
Pharmacology - DRUGS FOR DIABETES (MADE EASY)
Supporting Evidence This meta-analysis examined the relationship between therapeutic decreases in proteinuria in patients with type 2 diabetes and the length of independence from dialysis.
Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol.
Szentmiklósi, András József Absztrakt: Angiotensin-converting-enzyme inhibitors are a phmaceutical drugs used to treat several diseases such as hypertension and heart failure. During the passage of vessels in the lungs and renal vasculature, Ang I is generated by the action of renin on angiotensinogen which is then converted into Ang II by the action of an exopeptidase called ACE Peter R et al. This is where ACE inhibitors comes
Effects of losartan on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type-2 diabetes. A comparison of spirapril and isradipine in patients with diabetic nephropaty and hypertension.
Blood Press. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease.
A tételhez tartozó fájlok
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria Lancet. Significantly fewer patients in the ramipril group developed a new diagnosis of diabetes vs ; RR, 0. The rates of new-onset diabetes were Dose titration was by dose doubling and addition of atenolol mg or enalapril mg.
Follow-up was over approximately years. The co-amilozide group developed new diabetes at a rate of 4.
متعلقہ بک لسٹیں
LIFE — 89, patients aged years mean age 67 years with hypertension and documented LVH were randomly assigned to once-daily lisinopril dosage for diabetes atenolol-based treatment and followed for at least 4 years mean 4. Lisinopril dosage for diabetes occurred in patients receiving losartan and receiving atenolol.
Effects of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. Major Outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.